# Safi Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/safi-biotherapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.safi.bio
- Total disclosed funding: $9.7M
- Latest round: Grant (Nov 3, 2026)
- Investors on record: 2

## About

Founded in 2019 and based in Massachusetts, US, Safi Biotherapeutics, Inc. operates as a preclinical stage blood cell therapy company. The company was founded by its CEO, Doug McConnell, Jon Mogford, and Michael Mansour. In September 2024, Safi Biotherapeutics, Inc. raised USD 5 million in seed funding led by J2 Ventures.

Safi Biotherapeutics engages in the development of manufactured red blood cells (mRBCs). The company offers a variety of blood cell therapies, including red blood cells for trauma, which can be used to treat patients who have suffered blood loss due to injuries; and tailored red blood cells for specific transfusions, which develop red blood cells that are designed for patients with conditions like sickle cell disease.

The company plans to utilize the September 2024 funding raised to expedite the regulatory process and clinical production to submit an IND and begin initial clinical trials.

## Funding rounds

- Grant, Nov 3, 2026, $4.7M — Medical Technology Enterprise Consortium (MTEC)
- Seed, Sep 11, 2024, $5M — J2 Ventures

## Investors

- J2 Ventures (https://capitalatlas.ai/funds/j2-ventures) — Seed
- Medical Technology Enterprise Consortium (MTEC) — Grant